DSS, INC.

Overview

Compare with Sonoco, Graphic Packaging or Packaging Corporation of America, or pick any stock.

• TickerDSS on NYSE¹
• IndustryPaperboard Containers & Boxes¹
• HeadquartersWest Henrietta, New York¹
• Incorporated inNY²
• Business address275 Wiregrass Pkwy, West Henrietta, Ny 14586²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

DSS BioHealth Security, Inc. Its subsidiaries are currently operating in Houston, TX and Rochester, NY.⁴ From its latest annual report

Corporate structure

DSS, INC. sits at the top of its group. 32 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What DSS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Real estate and locations

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

The corporate group and the packaging division has occupied an approximate 105,000 square foot leased facility, located at 275 Wiregrass Parkway, Henrietta, New York since March 2022. This lease expires twelve years and 3 months later. Base rents escalate from $61,000 per month in year one to $78,000 per month in year twelve. In March 2021, the Company leased Suite 100 for approximately 3,800 sq. ft. in Houston for approximately $4,400 per month, in October 2022 the Company expanded the space by acquiring neighboring Suite 130. The Company currently leases both Suite 100 and Suite 130 at approximately 3,855 square feet for approximately $7,000 per month. The office is in Houston, Texas at 1400 Broadfield Blvd., Suite 100 and Suite 130, for corporate offices and subsidiary expansion.

Item 2 of the 10-K filed Mar 31, 2026.⁴

Leadership

Who has led DSS, INC., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerFrank D. Heuszel Jul 24, 2019 to Apr 18, 2023¹⁵
• Chief executive officerJeffrey Ronaldi Jul 8, 2013 to Mar 22, 2018¹⁶
• Chief executive officerPatrick White Nov 14, 2008 to Nov 21, 2012¹⁷
• PresidentRobert B. Bzdick Sep 13, 2013 to Jan 13, 2017¹⁸
• PresidentMichael J. Roy May 23, 2011 to Jul 18, 2011¹⁹
• PresidentPeter Ettinger Jul 6, 2006 to Dec 27, 2006²⁰
• Chief financial officerTodd D. Macko Nov 4, 2020 to Nov 4, 2020²¹
• Chief financial officerPhilip A. Jones Sep 29, 2011 to Dec 19, 2016²²
• Chief financial officerPhilip L. Jones Jun 8, 2009 to Jun 8, 2009²³
• Chief operating officerJason Grady Jul 18, 2019 to Jul 24, 2019²⁴
• Chief operating officerPeter Hardigan Jul 8, 2013 to Dec 19, 2014²⁵
• Chief operating officerRobert B. Bzdick Mar 1, 2010 to Nov 21, 2012²⁶

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• AMRE Asset Management, Inc. Nevada³
• Alset Innovations, Inc. Texas³
• American First Wealth Management, Inc. (formally DSS Wealth Management, Inc.) Texas³
• American Pacific Financial Texas³
• BioLife Sugar, Inc. Nevada³
• DSS Administrative Group, Inc. New York³
• DSS Asset Management, Inc. Texas³
• DSS BioHealth Security, Inc. Nevada³
• DSS BioMedical International, Inc. Nevada³
• DSS Biolife International, Inc. Nevada³
• DSS Blockchain Security, Inc. Nevada³
• DSS Financial Management, Inc. Texas³
• DSS PureAir, Inc. Texas³
• DSS Robot, Inc. Nevada³
• DSS Securities, Inc. Nevada³
• DSS Technology Management, Inc. Nevada³
• DSS, Inc. New York³
• Decentralized Sharing Systems, Inc. Nevada³
• Gigenomics Solutions, Inc Texas³
• Global BioLife, Inc. Texas³
• Global BioMedical, Inc. Nevada³
• HWH World, Inc. Texas³
• Happy Sugar, Inc. Nevada³
• Impact BioLife Science, Inc. Nevada³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• DOCUMENT SECURITY SYSTEMS INCMar 26, 2003 to Oct 1, 2021²
• NEW SKY COMMUNICATIONS INCNov 17, 1997 to Nov 13, 2002²

Timeline

1. Sep 21, 20268-K Entered a material agreement⁵⁸
2. Jun 25, 20268-K Entered a material agreement⁵⁹
3. Mar 31, 20268-K Entered a material agreement⁶⁰
4. Feb 5, 20268-K Entered a material agreement; Other events⁶¹
5. Dec 5, 20258-K Shareholder vote⁶²
6. Jul 30, 20258-K Entered a material agreement⁶³
7. Jul 1, 20258-K Change of auditor⁶⁴
8. Feb 6, 20258-K Entered a material agreement⁶⁵
9. Dec 30, 20248-K Entered a material agreement; Unregistered sale of shares⁶⁶
10. Dec 16, 20248-K Entered a material agreement; Unregistered sale of shares⁶⁷
11. Dec 9, 20248-K Shareholder vote⁶⁸
12. Oct 22, 20248-K Earlier financial statements no longer reliable⁶⁹
13. Jul 24, 2019New chief executive Frank D. Heuszel becomes CEO¹⁵
14. Jul 8, 2013New chief executive Jeffrey Ronaldi becomes CEO¹⁶
15. Nov 14, 2008New chief executive Patrick White becomes CEO¹⁷

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026⁷⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

143 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 44 major events, 24 insider forms, 18 large holders, 35 other. The latest 20:

1. Sep 21, 20268-K EDGAR
2. Sep 8, 2026SCHEDULE 13D/A EDGAR
3. Sep 8, 20264 EDGAR
4. Sep 4, 2026424B5 EDGAR
5. Aug 14, 202610-Q EDGAR
6. Jul 9, 2026SCHEDULE 13D/A EDGAR
7. Jul 9, 20264 EDGAR
8. Jun 25, 20268-K EDGAR
9. Jun 9, 2026RW EDGAR
10. May 15, 202610-Q EDGAR
11. May 14, 2026DEF 14C EDGAR
12. Apr 24, 2026S-1/A EDGAR
13. Apr 23, 2026PRE 14C EDGAR
14. Apr 17, 2026S-1 EDGAR
15. Apr 10, 2026DRS EDGAR
16. Mar 31, 20268-K EDGAR
17. Mar 31, 202610-K EDGAR
18. Feb 17, 2026DEF 14C EDGAR
19. Feb 6, 2026PRER14C EDGAR
20. Feb 5, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 12 buys and 3 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Fai ChanSCHEDULE 13D/A, 11 filings Mar 15, 2022 to Sep 8, 2026⁷¹
• CVI Investments, Inc.SC 13G/A, 1 filing Feb 14, 2022⁷²
• SABBY MANAGEMENT, LLCSC 13G/A, 1 filing Jan 3, 2022⁷³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How DSS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARDSS, INC.¹
• CIK0000771999
• Employer ID (EIN)16-1229730⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁴
• Incorporated inNew York⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2650 Paperboard Containers & Boxes¹
• SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance¹
• Business address275 Wiregrass Pkwy, West Henrietta, NY 14586¹
• Phone585 232 1500¹
• Shares outstanding10,042,518 as of Aug 5, 2026¹³
• Public float$2.8M as of Jun 30, 2025⁴
• AuditorHTL International, LLC, Houston, Texas PCAOB ID 7000; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceNov 17, 1997¹
• Filings1,089 in all: 8-K (312), 4 (230), 10-Q (76), CORRESP (48), 3 (42), SC 13D/A (31), UPLOAD (28), 425 (27)¹
  All 62 form types

  DEF 14A (25), 10-K (24), 424B5 (23), 8-K/A (13), 424B3 (12), EFFECT (12), SC 13D (12), 10QSB (11), S-3 (11), S-3/A (11), DEFA14A (10), 4/A (9), 10-K/A (8), PRE 14A (7), D (6), S-1/A (6), S-8 (6), 10KSB (5), PREC14A (5), S-4/A (5), SC 13G (5), SCHEDULE 13D/A (5), 10-Q/A (4), DFAN14A (4), S-1 (4), SC 13G/A (4), 3/A (3), DEF 14C (3), DEFR14A (3), NT 10-Q (3), PRE 14C (3), REGDEX (3), 10KSB/A (2), 424B1 (2), CT ORDER (2), FWP (2), PRER14A (2), REGDEX/A (2), RW (2), S-1MEF (2), 10QSB/A (1), 144 (1), 5 (1), 8-A12B (1), ARS (1), CERTAMX (1), DEFA14C (1), DEFC14A (1), DRS (1), NT 10-K (1), PREN14A (1), PRER14C (1), S-3MEF (1), S-4 (1)

• Latest filingsAnnual report (10-K) Mar 31, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) Oct 20, 2025
  Latest 8-K (8-K) Sep 21, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks DSS, INC. names in Item 1A of its 10-K filed Mar 31, 2026: 23 risks under these headings, as written.⁴

• The value of our intangible assets and investments may not be equal to their carrying values.
• We have secured indebtedness, and a potential risk exists that we may be unable to satisfy our obligations to pay interest and principal thereon when due or negotiate acceptable extensions or settlements.
• A significant amount of our revenue is derived by one customers.
• We may face intellectual property infringement or other claims against us, our customers or our intellectual property that could be costly to defend and result in our loss of significant rights.
• Certain of our recently developed products are not yet commercially accepted and there can be no assurance that those products will be accepted, which would adversely affect our financial results.
• The results of our research and development efforts are uncertain and there can be no assurance of the commercial success of our products.
• The markets in which we operate are highly competitive, and we may not be able to compete effectively, especially against established industry competitors with greater market presence and financial resources.
• If we are unable to respond to regulatory or industry standards effectively, our growth and development could be delayed or limited.
• Breaches in security, whether cyber or physical, and other disruptions and/or our inability to prevent or respond to such breaches, could diminish our ability to generate revenues or contain costs, compromise our assets, and negatively impact our business in other ways.
• Our investments in Asia are subject to unique risks and uncertainties, including tariffs and trade restrictions.
• Future growth in our business could make it difficult to manage our resources.
• If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to remain competitive, continue to expand our technology or pursue growth.

Legal proceedings

DSS BioHealth Holdings, Inc. (“DSS BioHealth”) is the plaintiff in an action pending in the 281st Judicial District Court of Harris County, Texas, styled DSS BioHealth Holdings, Inc. v. Puradigm LLC, Ryan Beagley, Derik Sandstrom, and Padraig Lawlor, Cause No. 2024-73209. DSS BioHealth, as assignee of DSS PureAir, Inc., seeks to recover amounts due under a $5,000,000 secured convertible note dated May 14, 2021 and a $210,000 secured promissory note dated May 9, 2022, as well as to enforce related security and guaranty agreements. DSS BioHealth alleges that Puradigm LLC has failed to make required payments on the notes and that the individual defendants have failed to perform under their personal guaranties. Puradigm has filed counterclaims against DSS BioHealth and certain affiliates alleging, among other things, breach of contract, fraud, negligent misrepresentation, deceptive trade practices, conspiracy, and promissory estoppel, and seeks monetary relief in excess of $1,000,000. The case is in the pre-trial stage, and the parties are engaged in motion practice and discovery. DSS BioHealth believes it has meritorious claims and valid defenses to the counterclaims, but the outcome of the litigation, including any potential losses or recoveries, cannot be predicted at this time, and no assurance can be given as to the ultimate resolution or its impact on the Company’s financial statements.

We may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable.

The opening of Item 3, Legal Proceedings.⁴